| Zacks Company Profile for Alkermes plc (ALKS : NSDQ) |
|
|
| |
| • Company Description |
| Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.
Number of Employees: 2,050 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $30.10 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,770,199 shares |
| Shares Outstanding: 166.65 (millions) |
| Market Capitalization: $5,016.16 (millions) |
| Beta: 0.53 |
| 52 Week High: $36.32 |
| 52 Week Low: $25.17 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-11.18% |
-10.41% |
| 12 Week |
1.96% |
1.84% |
| Year To Date |
7.58% |
7.05% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Richard F. Pops - Chairman and Chief Executive Officer
Joshua Reed - Senior Vice President; Chief Financial Officer
Samuel J. Parisi - Vice President; Finance
Shane M. Cooke - Director
Nancy S. Lurker - Director
|
|
Peer Information
Alkermes plc (CORR.)
Alkermes plc (RSPI)
Alkermes plc (CGXP)
Alkermes plc (BGEN)
Alkermes plc (GTBP)
Alkermes plc (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G01767105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/07/26
|
|
Share - Related Items
Shares Outstanding: 166.65
Most Recent Split Date: 5.00 (2.00:1)
Beta: 0.53
Market Capitalization: $5,016.16 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.12 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.82 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 4.89% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 05/07/26 |
|
|
|
| |
